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Cognitive therapy for people with schizophrenia spectrum 
disorders not taking antipsychotic drugs: a single-blind 
randomised controlled trial
Anthony P Morrison, Douglas Turkington, Melissa Pyle, Helen Spencer, Alison Brabban, Graham Dunn, Tom Christodoulides, Rob Dudley, 
Nicola Chapman, Pauline Callcott, Tim Grace, Victoria Lumley, Laura Drage, Sarah Tully, Kerry Irving, Anna Cummings, Rory Byrne, 
Linda M Davies, Paul Hutton
Summary
Background Antipsychotic drugs are usually the fi rst line of treatment for schizophrenia; however, many patients 
refuse or discontinue their pharmacological treatment. We aimed to establish whether cognitive therapy was eff ective 
in reducing psychiatric symptoms in people with schizophrenia spectrum disorders who had chosen not to take 
antipsychotic drugs.
Methods We did a single-blind randomised controlled trial at two UK centres between Feb 15, 2010, and May 30, 2013. 
Participants aged 16–65 years with schizophrenia spectrum disorders, who had chosen not to take antipsychotic drugs 
for psychosis, were randomly assigned (1:1), by a computerised system with permuted block sizes of four or six, to 
receive cognitive therapy plus treatment as usual, or treatment as usual alone. Randomisation was stratifi ed by study 
site. Outcome assessors were masked to group allocation. Our primary outcome was total score on the positive and 
negative syndrome scale (PANSS), which we assessed at baseline, and at months 3, 6, 9, 12, 15, and 18. Analysis was 
by intention to treat, with an ANCOVA model adjusted for site, age, sex, and baseline symptoms. This study is 
registered as an International Standard Randomised Controlled Trial, number 29607432.
Findings 74 individuals were randomly assigned to receive either cognitive therapy plus treatment as usual (n=37), or 
treatment as usual alone (n=37). Mean PANSS total scores were consistently lower in the cognitive therapy group 
than in the treatment as usual group, with an estimated between-group eff ect size of −6·52 (95% CI −10·79 to −2·25; 
p=0·003). We recorded eight serious adverse events: two in patients in the cognitive therapy group (one attempted 
overdose and one patient presenting risk to others, both after therapy), and six in those in the treatment as usual 
group (two deaths, both of which were deemed unrelated to trial participation or mental health; three compulsory 
admissions to hospital for treatment under the mental health act; and one attempted overdose).
Interpretation Cognitive therapy signifi cantly reduced psychiatric symptoms and seems to be a safe and acceptable 
alternative for people with schizophrenia spectrum disorders who have chosen not to take antipsychotic drugs. 
Evidence-based treatments should be available to these individuals. A larger, defi nitive trial is needed.
Funding National Institute for Health Research.
Introduction
Antipsychotic drugs are usually the fi rst line of treatment 
for schizophrenia, and clinical guidelines report clear 
benefi ts in terms of symptom reduction.1 Furthermore, 
fi ndings have shown that antipsychotic use is associated 
with decreased mortality overall,2 perhaps because of a 
protective eff ect against suicide,2 and with signifi cant 
benefi ts for relapse prevention.3 However, evidence also 
shows that many patients choose to refuse or discontinue 
their pharmacological treatment. The largest trial4 to 
compare atypical antipsychotics found that 74% of 
patients with schizophrenia discontinued their drugs 
over 18 months, and rates of drug non-compliance in 
patients with schizophrenia can be as high as 40–50%.5 
Patients with psychosis are often ambivalent about taking 
drugs,6 and evidence suggests that the eff ectiveness of 
such drugs has been overestimated, whereas the severity 
of their adverse eff ects have been underestimated.7 A 
systematic review concluded that the improvements 
claimed for antipsychotics are of questionable clinical 
relevance,8 and a multiple-treatments meta-analysis9 
showed that although diff erences in effi  cacy between 
antipsychotics and placebo were noted, they were smaller 
than those for most of the analysed adverse eff ects.10 
Research suggests that adverse eff ects include structural 
abnormalities in brain volume,11 increased risk of sudden 
cardiac death,12 and substantial weight gain induced by 
antipsychotics,13 which is associated with cardiovascular 
and metabolic risks.
Given the cost-benefi t profi le, some choices to refuse 
antipsychotics might suggest a rational decision rather 
than an irrational consequence of psychosis. Many 
people admitted to hospital with psychosis retain the 
capacity to make decisions about treatment,14 and a 
review of choice and decision making in people using 
mental health services concluded that service users want 
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to be off ered more than just drugs.15 Cognitive therapy 
has proven to be eff ective when delivered in combination 
with antipsychotic drugs, with fi ndings from several 
meta-analyses showing robust support for this approach.16 
Our exploratory single-group study assessed cognitive 
therapy in 20 participants with schizophrenia spectrum 
disorders who had not been taking antipsychotic drugs 
for at least 6 months.17 We noted signifi cant benefi cial 
eff ects on primary and secondary outcomes at the end of 
treatment and follow-up, and good acceptability, and no 
patients signifi cantly deteriorated. However, such a trial 
clearly suggests the possibility of bias resulting from 
allegiance eff ects and non-masked ratings; the absence 
of randomisation to a control group was also problematic. 
These methodological limitations probably resulted in 
infl ated estimates of treatment eff ects because cognitive 
therapy for psychosis trials that attempt masking are 
associated with a reduction of eff ect sizes of nearly 60%.16
In this study, we aimed to assess the feasibility and 
eff ectiveness of cognitive therapy for people with 
schizophrenia spectrum disorders who had decided not 
to take antipsychotic drugs.
Methods
Study design and participants
We did this single-blind, randomised, controlled, pilot 
trial between Feb 15, 2010, and May 30, 2013, at two UK 
centres in Manchester and Newcastle.
Eligible participants aged 16–65 years were in contact 
with mental health services, and either met International 
Classifi cation of Diseases–tenth revision (ICD-10) criteria 
for schizophrenia, schizoaff ective disorder, or delusional 
disorder, or met entry criteria for an early intervention 
for psychosis service (operationally defi ned with the 
Positive and Negative Syndrome Scale [PANSS]) to allow 
for diagnostic uncertainty in early phases of psychosis 
and the fact that most early-episode cases in the UK will 
receive their services from such specialist teams, 
consistent with NICE guidelines. Participants had also 
had either at least 6 months without antipsychotic drugs 
and continuing symptoms or had never received 
antipsychotics and had chosen not to; all participants 
scored at least 4 on PANSS delusions or hallucinations, 
or at least 5 on suspiciousness or persecution, conceptual 
disorganisation, or grandiosity. All participants were 
identifi ed via care coordinators and relevant mental 
health staff  within participating mental health trusts at 
the two study sites. Exclusion criteria were present 
receipt of antipsychotic drugs; moderate to severe 
learning disability; organic impairment; participants not 
having the capacity to consent to research participation; 
non-English-speaking participants (because their 
inclusion would prevent the use of standardised 
assessment techniques); acute inpatient care settings; 
receipt of cognitive therapy for psychosis or previous 
cognitive therapy for other disorders in the past 2 years; 
and a primary diagnosis of substance or alcohol abuse. 
Diagnosis was established with case notes and the ICD-
10 checklist. A consultant psychiatrist (DT) confi rmed all 
diagnoses, with application of ICD-10 to vignettes based 
on the PANSS assessments for all cases, including those 
in early intervention services who did not have a formal 
diagnosis in their medical records. Further details about 
our ascertainment strategy, referral sources, reasons for 
choosing not to take antipsychotics, and additional 
participant characteristics are provided elsewhere.18 Our 
protocol was approved by the National Research Ethics 
Service of the UK’s National Health Service (reference 
09/H1014/53). All participants provided written informed 
consent.
After original ethical approval of the trial in October 
2009, several amendments to the protocol were made: 
addition of secondary measures including the CHOICE 
and EQ-5D; addition of some secondary measures for an 
add-on hypothesis about childhood trauma at month 3; 
removal of some secondary measures at months 3, 6, and 
15 to reduce participant burden; the ability to retain 
people if they lose capacity, which was an event that did 
not actually take place throughout the trial; and a minor 
change to the exclusion criteria to signify the population 
and increase generalisability (allowing inclusion of those 
with substance dependence as long as it was not the 
primary diagnosis).
Randomisation and masking
Participants were randomly assigned electronically (1:1) 
by a computerised system (Open Clinical Data 
Management System [OpenCDMS], version 1.7.4)19 with 
permuted block sizes of four or six, to receive cognitive 
therapy plus treatment as usual, or treatment as usual 
alone. Because of the variability of treatment as usual, 
and because this control is dependent on local service 
confi gurations and specifi c sources of referral to the 
trial, randomisation was fi rst stratifi ed by study site. 
OpenCDMS then sent out email notifi cations of the 
allocation to the therapists and trial manager. Thus, 
assessors were masked to group allocation and 
randomisation was independent. We used many 
strategies to achieve masked ratings: research workers 
were not involved in the randomisation process; 
therapists were required to consider room use and diary 
arrangements in view of potential blind breaks; and 
patients were reminded by assessors not to talk about 
treatment allocation. 13 blind breaks (representing 18% 
of participants) were reported by research assistants 
with a standard form: four (31%) of these breaks were 
with treatment as usual  and nine (69%) with cognitive 
therapy. In cases where concealment was broken, 
another rater assessed the patient for all subsequent 
assessments or the ratings were discussed with a masked 
rater and consensus reached. This assessment strategy 
ensured that only a minority of a total of about 500 
assessments had their validity threatened by absence of 
rater masking.
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Procedures
In addition to treatment as usual, participants allocated 
to the therapy group received cognitive therapy on the 
basis of a specifi c cognitive model.20 26 sessions were 
off ered on a roughly weekly basis for a maximum of 
9 months, plus up to four booster sessions in the 
subsequent 9 months. Cognitive therapy requires an 
individualised, problem-oriented approach and 
incorporates a manualised process of assessment and 
formulation. The central features of our approach to 
treatment of psychosis involve normalisation and 
evaluation of the appraisals that people make, helping 
them to test such appraisals with use of behavioural 
experiments, and helping them to identify and modify 
unhelpful cognitive and behavioural responses. A more 
detailed analysis of the treatment strategies can be found 
in our treatment manuals.21,22 Fidelity to the treatment 
protocol was ensured by regular supervision of the 
therapists and was assessed by rating of recordings of 
sessions with a version of the Cognitive Therapy Scale-
Revised23 (CTS-R), and by review of written, structured 
session records that were completed by the therapist 
after each session. Therapy supervision was provided by 
means of regular meetings between therapists and the 
chief investigator. Ten sessions were rated on the CTS-R, 
and all were rated as competent or above.
Eight therapists (two at the Manchester sites and six in 
Newcastle) contributed to the delivery of cognitive 
therapy. The number of participants treated by each 
therapist ranged between two and 18 (mean 4·6, SD 5·5). 
Five therapists were clinical psychologists (doctoral level), 
two were nurses with an additional specialist qualifi cation 
in cognitive therapy, and one was a consultant psychiatrist 
with specialist training in cognitive therapy. All therapists 
received additional training associated with the trial 
manual, and regular supervision.
All participants received treatment as usual plus 
regular monitoring (incorporating a PANSS assessment 
from a research assistant), which provided benefi ts over 
routine care because it aimed to provide warm, empathic, 
and non-judgmental face-to-face contact, supportive 
listening, signposting to appropriate local services for 
unmet needs, and crisis management when needed 
(usually by referral to a local crisis team, early intervention 
service, or psychiatric liaison within emergency 
departments). Treatment as usual was variable across 
both sites, although both were chosen partly because 
they had comprehensive early intervention services. In 
practice, participants within these services received 
regular care-coordination and psychosocial interventions, 
including the off er of family interventions, whereas 
individuals from other community-based services often 
received little more than irregular contact with care 
coordinators, and many of these participants were 
discharged by their clinical teams during the trial for 
non-attendance or continued reluctance to accept 
medicine.
Outcomes
Our primary outcome was  total score on the PANSS,24 
which we assessed at baseline, and at months 3, 6, 9, 12, 
15, and 18. The PANSS is a clinician-administered, thirty-
item, semi-structured interview consisting of seven items 
assessing positive symptomatology (eg, hallucinations, 
delusions, conceptual disorganisation); seven items 
assessing negative symptomatology (eg, blunted eff ect, 
passive or apathetic social avoidance); and 16 items 
assessing general psychopathology (eg, depression, 
anxiety, poor insight, guilt). All items are scored 
between 1 (not present) and 7 (severe). Several studies 
have shown the reliability and validity of the PANSS.25 We 
assessed inter-rater reliability regularly (on nine 
occasions) throughout the trial, with both video and role-
play assessments with all trial raters (n=5) participating; 
intra-class correlation coeffi  cients indicated good 
reliability between raters (mean 0·83, SD 0·12).
Secondary outcomes included dimensions of psychotic 
experiences such as severity, distress and disability, 
measured with the Psychotic Symptom Rating Scales;26 
a clinician-administered, semi-structured interview 
consisting of 11 items assessing dimensions of auditory 
hallucinations, and six items assessing dimensions of 
delusional beliefs. All items are scored from 0 to 4, with 
higher scores showing more severe phenomena. Factor 
analyses show that the delusions scale has two subscales 
(emotional and cognitive) and the hallucinations scale 
has three subscales (emotional, physical, and cognitive).26 
We also included a user-defi ned measure of recovery 
(QPR27), which is a questionnaire developed col-
laboratively with service users that measures subjective 
recovery. We used a 15-item version of the questionnaire, 
which is more reliable than the original 22-item version 
(α 0·91). Participants rated their agreement with 
statements on a 5-point Likert scale, from strongly 
disagree to strongly agree. We assessed social func-
tioning with the Personal and Social Performance 
Scale;28 a 100-point, single-item rating scale based on an 
interview that assesses patient’s functioning in four 
areas (socially useful activities, personal and social 
relationships, self-care, and disturbing and aggressive 
behaviour). We assessed emotional distress with the 
Beck Depression Inventory for Primary Care (BDI-PC)29 
and the Social Interactions Anxiety Scale (SIAS).30 The 
SIAS has a recommended cutoff  of greater than 36, 
showing a probable diagnosis of social anxiety disorder, 
and the BDI-PC has a recommended cutoff  of greater 
than 3, showing a probable diagnosis of major depressive 
disorder. We recorded prescriptions of antipsychotic and 
other psychiatric drugs. Most assessments were done in 
the participant’s home. Several other measures were 
administered (such as EQ-5D, the CHOICE, the 
Metacognitions Questionnaire, and the Personal Beliefs 
about Experiences Questionnaire), but these were 
intended for secondary analyses, such as predictors of 
outcome and cost eff ectiveness. We report on all 
Articles
1398 www.thelancet.com   Vol 383   April 19, 2014
outcomes that were specifi ed in our published protocol 
and analysis plan.18
After randomisation, all participants received monitoring 
assessments every 3 months up to a total of 18 months. Our 
variable follow-up period meant that participants recruited 
in the fi rst 18 months of the study (from February, 2010, to 
August, 2011) were planned to receive the full 18 months of 
follow-up. Participants recruited thereafter were off ered 
steadily reducing follow-up periods dependent on time of 
recruitment (this approach was used to maximise value for 
money, with a view to obtain as much data as possible for 
participants recruited in early phases of the trial, with 
shorter follow-up periods for those recruited in later 
phases). The minimum follow-up period was 9 months; 
follow-ups at 12, 15, and 18 months  had fewer participants 
because those most recently recruited could not be followed 
up at these timepoints within the funded resources.
Statistical analysis
With 30 participants per group, with a t test at a two-tailed 
signifi cance of 0·05, we had over 80% power to detect an 
eff ect size of 0·8; if the signifi cance level were changed to 
15%, which might be appropriate for a pilot study, 
30 participants per group would provide 80% power to 
detect an eff ect size of 0·6. We chose a recruitment target 
of 80 (40 per site) allowing for a dropout rate of up to 25%.
Statistical analysis was agreed with the data monitoring 
and ethics committee, and the a-priori analysis plan was 
published.18 Analyses were undertaken in STATA 
(version 12). Primary analysis was by intention to treat. 
Changes in all primary and secondary outcomes were 
analysed with STATA’s xtreg command to fi t random-
eff ects regression models (essentially, repeated measures 
ANCOVAs) with summed scores as dependent variables, 
Figure: Trial profi le
Possible numbers of participants refers to the maximum possible at this timepoint on the basis of variable length 
of follow-up time.
143 participants referred
74 randomised
37 assigned to cognitive therapy plus monitoring 37 assigned to monitoring only
3 months (possible n=37)
7 lost to follow-up
2 discontinued (withdrawn)
3 months (possible n=37)
10 lost to follow-up
 2 discontinued (withdrawn)
6 months (possible n=37)
8 lost to follow-up
4 discontinued (withdrawn)
6 months (possible n=37)
14 lost to follow-up
 3 discontinued (withdrawn)
12 months (possible n=34)
12 lost to follow-up
 4 discontinued (withdrawn)
12 months (possible n=34)
7 lost to follow-up
6 discontinued
 5 withdrawn
 1 died
15 months (possible n=30)
12 lost to follow-up
 4 discontinued (withdrawn)
15 months (possible n=30)
8 lost to follow-up
5 discontinued
 3 withdrawn
 2 died
18 months (possible n=26)
3 lost to follow-up
5 discontinued (withdrawn)
18 months (possible n=25)
3 lost to follow-up
4 discontinued
 2 withdrawn
 2 died
9 months (possible n=37)
8 lost to follow-up
4 discontinued (withdrawn)
9 months (possible n=37)
6 lost to follow-up
6 discontinued
 5 withdrawn
 1 died
69 ineligible
 48 excluded
 22 less than threshold on PANSS
 2 had evidence of organic impairment
 10 were taking antipsychotic drugs or had done 
  in the past 6 months
 1 received cognitive behavioural therapy for 
  psychosis or any other disorder within the 
  past 2 years
 2 were receiving inpatient care
 3 had no care coordination
 5 had a primary diagnosis of psychosis
 3 were unable to engage before the end of the 
  trial
 21 declined involvement
 18 declined before assessment of eligibility
 3 declined after being assessed as eligible
CT plus TAU 
(n=37)
TAU only 
(n=37)
Age (years) 32·95 (13·11) 29·68 (11·95)
Sex
Male 17 (46%) 22 (59%)
Female 20 (54%) 15 (41%)
PANSS total 70·24 (13·75) 73·27 (13·42)
PANSS positive 20·30 (5·22) 21·65 (4·47)
PANSS negative 13·54 (3·17) 15·49 (5·26)
PANSS general 36·41 (7·94) 36·14 (7·05)
PSYRATS unusual beliefs (cognitive) 10·11 (4·18) 10·43 (2·91)
PSYRATS unusual beliefs (emotional) 5·17 (2·69) 5·00 (2·51)
PSYRATS voices (cognitive) 5·28 (5·13) 7·73 (5·23)
PSYRATS voices (emotional) 5·86 (6·43) 7·92 (5·93)
PSYRATS voices (physical) 5·62 (5·40) 7·37 (5·10)
PSP 56·84 (16·45) 50·03 (16·19)
QPR total 29·35 (11·15) 28·76 (11·78)
BDI-PC total 10·54 (5·21) 9·41 (4·03)
SIAS total 40·43 (19·76) 45·15 (15·19)
PANSS G12 (insight) 3·03 (1·67) 3·20 (1·67)
PANSS insight >3 (moderate or higher 
problems)
17 (46%) 17 (46%)
Data are mean (SD) or n (%), unless otherwise indicated. CT=cognitive therapy. 
TAU=treatment as usual. PANSS=positive and negative syndrome scale. 
PSYRATS=psychotic symptom rating scales. PSP=personal and social performance. 
QPR= questionnaire on the process of recovery. BDI-PC=Beck depression inventory 
for primary care. SIAS=social interaction anxiety scale.
Table 1: Baseline characteristics
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allowing for attrition and the variable follow-up times 
introduced by the trial design. Covariates included site, 
sex, age, and the baseline value of the relevant outcome 
measure. Use of these models allowed for analysis of all 
available data, in the assumption that data were missing at 
random,31 conditional on adjustment for centre, age, sex, 
and  baseline scores. The missing-at-random assumption 
seems to be the most realistic, in view of the planned 
variation in maximum follow-up times and the many other 
factors likely to aff ect drop-out; additionally,  the 
assumption is routinely used in analyses of data from 
longitudinal trials. We report numbers of participants in 
each group (completer-only data ie, observed cases) 
achieving improvement or deterioration in adjusted 
PANSS total scores,32 as has been recommended for trials 
using the PANSS.33 We report estimated treatment eff ects, 
with their standard errors, signifi cance levels, and 95% CIs. 
All treatment eff ects reported here are estimates of the 
eff ects common to all follow-up times.
Role of the funding source
The sponsor of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report, or in the decision to submit for 
publication. The corresponding author and GD had full 
access to all the data in the study and had the fi nal 
decision to submit for publication.
Results
The fi gure shows the trial profi le. 74 individuals were 
randomised to the cognitive therapy plus treatment as 
usual group (n=37), or the treatment as usual alone group 
3 months 6 months 9 months 12 months 15 months 18 months
CT (n=37) TAU (n=37) CT (n=37) TAU (n=37) CT (n=37) TAU (n=37) CT (n=34) TAU (n=34) CT (n=30) TAU (n=30) CT (n=26) TAU (n=25)
PANSS total 62·93 
(13·72); 
n=28
72·88 
(15·56); 
n=24
59·96 
(14·47); 
n=23
66·95 
(11·70); 
n=19
57·95 
(14·99); 
n=22
63·26 
(13·21); 
n=23
58·56 
(18·85); 
n=18
68·33 
(15·03); 
n=21
54·68 
(14·61); 
n=19
69·94 
(14·35); 
n=16
56·47 
(18·22); 
n=17
71·24 
(20·35); 
n=17
PANSS positive 18·14 
(5·34); 
n=28
21·71 
(5·83); 
n=24
17·04 
(5·36); 
n=23
18·32 
(4·40); 
n=19
16·00 
(5·94); 
n=22
17·00 
(4·85); 
n=23
16·32 
(7·94); 
n=19
18·62 
(5·26); 
n=21
14·05 
(5·36); 
n=19
19·44 
(5·75); 
n=16
14·63 
(6·18); 
n=19
18·83 
(7·26); 
n=18
PANSS negative 13·00 
(3·16);
n=28
14·88 
(5·77); 
n=24
12·48 
(3·63); 
n=23
13·95 
(3·76); 
n=19
12·5 
(3·38); 
n=22
14·26 
(4·21); 
n=23
12·61 
(4·24); 
n=18
15·95 
(5·89); 
n=21
12·05 
(3·85); 
n=19
16·19 
(5·49); 
n=16
12·53 
(2·83); 
n=17
16·59 
(6·65); 
n=17
PANSS general 31·79 
(7·89); 
n=28
36·29 
(8·26); 
n=24
30·43 
(8·63); 
n=23
34·68 
(7·17); 
n=19
29·45 
(7·68); 
n=22
32·00 
(6·98); 
n=23
29·78 
(7·95); 
n=18
33·76 
(7·80); 
n=21
28·58 
(7·71); 
n=19
34·31 
(7·10); 
n=16
29·22 
(10·51); 
n=18
35·82 
(9·74); 
n=17
QPR total 33·91 
(11·36); 
n=23
29·34 
(12·64); 
n=21
31·52 
(15·12); 
n=21
30·42 
(10·99); 
n=19
35·12 
(11·76); 
n=25
32·10 
(8·80); 
n=21
34·00 
(16·41); 
n=16
31·87 
(9·64); 
n=15
41·63 
(11·22); 
n=16
29·69 
(9·71); 
n=13
39·50 
(15·46); 
n=16
29·38 
(8·76); 
n=16
PSP 59·81 
(16·55); 
n=27
49·70 
(14·46); 
n=24
59·74 
(17·88); 
n=23
51·89 
(16·09); 
n=19
65·00 
(12·75); 
n=23
56·74 
(15·02); 
n=23
65·37 
(17·63); 
n=19
52·95 
(15·50); 
n=21
65·84 
(18·22); 
n=19
53·53 
(18·75); 
n=15
64·74 
(20·24); 
n=19
55·94 
(20·29); 
n=18
BDI 7·83
(5·58); 
n=24
9·65 
(4·69); 
n=23
7·57 
(5·89); 
n=21
7·37
(3·61); 
n=19
6·35 
(5·93); 
n=26
7·14
(3·35); 
n=21
7·44 
(6·34); 
n=18
7·00
(3·54); 
n=17
4·50 
(4·05); 
n=16
7·38
(4·29); 
n=13
5·50 
(5·63); 
n=16
7·38
(5·16); 
n=16
SIAS 35·18 
(18·75); 
n=22
44·53 
(13·21); 
n=19
37·63 
(18·40); 
n=19
40·78 
(12·88); 
n=18
31·71 
(16·34); 
n=24
40·48 
(13·88); 
n=21
30·00 
(22·38); 
n=15
41·86 
(14·87); 
n=14
28·59 
(18·21); 
n=17
45·27 
(16·44); 
n=11
31·31 
(20·87); 
n=16
44·06 
(18·21); 
n=16
PSYRATS delusions
(cognitive)
7·82
(4·97);
n=27
9·57
(3·75); 
n=23
7·78 
(4·88); 
n=23
8·00
(3·41); 
n=18
6·63 
(5·32); 
n=24
7·28 
(4·99); 
n=25
6·00 
(5·75); 
n=19
8·63
(4·21); 
n=19
3·47 
(4·66); 
n=19
8·81
(4·36); 
n=16
5·32 
(5·39); 
n=19
7·18
(4·76); 
n=17
PSYRATS delusions 
(emotional)
3·85
(3·21);
n=27
4·78 
(2·88); 
n=23
3·61 
(3·24); 
n=23
3·28
(3·14); 
n=18
3·21 
(3·36); 
n=24
2·92
(2·75); 
n=25
3·05
(3·37); 
n=19
4·11
(2·94); 
n=19
1·26 
(2·51); 
n=19
3·38
(2·68); 
n=16
2·21 
(2·72); 
n=19
3·47
(2·63); 
n=17
PSYRATS voices
(cognitive)
3·52
(4·78);
n=27
6·78
(5·78); 
n=23
2·26 
(3·89); 
n=23
6·00
(5·45); 
n=19
2·73 
(4·46); 
n=26
4·82 
(5·29); 
n=27
3·25
(3·70); 
n=20
5·37
(5·92); 
n=19
2·42 
(3·88); 
n=19
5·94
(5·13);
n=17
0·79 
(2·37); 
n=19
5·65
(5·36); 
n=17
PSYRATS voices
(emotional)
3·41
(5·40);
n=27
5·96 
(6·09); 
n=23
2·35 
(4·25); 
n=23
4·26
(5·95); 
n=19
2·81 
(5·02); 
n=26
5·07 
(5·90); 
n=27
3·74
(5·53); 
n=19
4·26
(6·04); 
n=19
2·00 
(3·84); 
n=19
5·12
(6·12); 
n=17
0·50 
(2·12); 
n=18
6·00 
(6·49); 
n=18
PSYRATS voices
(physical)
4·37
(5·49);
n=27
7·04
(5·92); 
n=23
3·00 
(4·84); 
n=23
5·37
(5·20); 
n=19
3·31 
(4·76); 
n=26
4·82 
(5·41); 
n=27
4·35 
(4·67); 
n=20
5·76
(5·93); 
n=21
2·58 
(4·02); 
n=19
5·94 
(4·89); 
n=17
1·11 
(3·32); 
n=19
6·83
(6·21); 
n=18
Data are mean (SD), unless otherwise indicated. CT=cognitive therapy. TAU=treatment as usual. PANSS=positive and negative syndrome scale. QPR=questionnaire on the process of recovery. PSP=personal and 
social performance. BDI=Beck depression inventory. SIAS=social interaction anxiety scale. PSYRATS=psychotic symptom rating scales.
Table 2: Primary and secondary outcome variables at months 3, 6, 9, 12, 15, and 18
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(n=37). We stopped before the target of 80 individuals in 
accordance with our recruitment timeline, on the basis of 
restricted resources, to ensure that we had the possibility 
to obtain 9 month data for all participants. Baseline 
characteristics were similar between groups (table 1).
Recruitment was fairly successful: we recruited over 
target in one of the two sites, and had a fi nal sample that 
was 93% of target (fi gure). Our referral to randomised 
ratio was 2:1, and only three (2%) of 143 referrals declined 
participation after being assessed as eligible, suggesting 
good willingness to be randomised, and to consider 
cognitive therapy, within this population (fi gure). 
Participants allocated to cognitive therapy received a 
mean of 13·3 sessions (SD 7·57; range 2–26), with each 
session lasting roughly 1 h (these fi gures do not include 
the four booster sessions that were available). Adherence 
to cognitive therapy was reasonably good, with no 
patients not attending any sessions, and 30 (82%) having 
at least six or more sessions. Retention within the trial 
was reasonable, with few discontinuations and 
withdrawals in each group (fi gure), and missing data 
rates of 29·7% at primary endpoint and 29·4% at follow-
up. 68 (92%) of participants had a diagnosis of 
schizophrenia, two (3%) were schizoaff ective, three (4%) 
had persistent delusional disorder, and one (1%) had 
psychosis not otherwise specifi ed.
For the primary outcome of PANSS total scores, mean 
scores were consistently less in the cognitive therapy 
group than in the treatment as usual group (table 2)—
low PANSS scores are preferable. This fi nding is shown 
in the estimates of treatment eff ect (table 3), with the 
estimated between-group eff ect size (unstandardised) for 
the PANSS total score equating to a standardised eff ect 
size (Cohen’s d) of 0·46. The eff ects on the positive and 
general subscales are consistent with this fi nding, but 
cognitive therapy seemed to have little or no eff ect  on 
negative symptoms (table 2). On the basis of the PANSS 
data, we noted, on average, no overall deterioration in 
either group (table 2).
For the secondary outcomes, the estimated treatment 
eff ects for the PSYRATS scores in table 3 are consistent 
with the fi ndings for the primary outcome, but not all are 
statistically signifi cant. For the other outcomes, we 
recorded a signifi cant eff ect in favour of cognitive therapy 
for social functioning (personal and social performance 
scale), but no diff erences on our measures of 
recovery (questionnaire on the process of recovery), 
depression (Beck depression inventory), or anxiety 
(social interaction anxiety scale; table 3). For no outcome 
did treatment eff ects vary with time of follow-up (we 
noted no signifi cant treatment by time interactions). 
By examination of the proportion of participants 
achieving good clinical outcomes in each disorder 
(defi ned by use of an improvement of >50% in adjusted 
PANSS total scores), we noted that, at 9 months, seven 
(32%) of 22 participants in the cognitive therapy group, 
and three (13%) of 23 from the treatment as usual group 
had achieved good clinical outcomes (table 4). At 
18 months seven (41%) of 17 receiving cognitive therapy 
and three (18%) of 17 receiving treatment as usual had 
achieved good clinical outcomes (table 4). Two 
participants in each group had signifi cant deterioration 
(defi ned by use of a deterioration of >50% in adjusted 
PANSS total scores; table 5). We recorded eight serious 
adverse events, two of which were in patients in the 
cognitive therapy group (both of which happened after 
therapy; one attempted overdose, one presenting risk to 
others) and six were in those in the treatment as usual 
group (two deaths, both of which were deemed unrelated 
to trial participation or mental health; three compulsory 
admissions to hospital for treatment under the mental 
health act and one attempted overdose). Table 5 shows 
data for type, number, and length of stay for voluntary 
hospital admissions. We recorded only one voluntary 
hospital admission in the follow-up phase, in a patient 
in the cognitive therapy group, which was voluntary and 
lasted 4 days. All serious adverse events and hospital 
admissions were in separate participants.
With regards to use of antipsychotic drugs throughout 
the lifetime of the trial, ten (4%) of 37 participants in the 
cognitive therapy group were prescribed antipsychotics 
after randomisation (eight during the treatment window 
and two during the follow-up phase) as were ten (4%) of 
37 in the treatment as usual group (nine during the 
treatment window and one during the follow-up phase). 
To explore the potential contribution that drugs might 
have had in individual participants, we assessed the 
extent of change in PANSS scores for those who 
commenced antipsychotics by 9 months and 18 months 
(table 4). Of patients in the cognitive therapy group 
prescribed antipsychotics in the treatment phase, one 
Estimate (SE)* 95% CI p value
PANSS total −6·52 (2·18) −10·79 to −2·25 0·003
PANSS positive −2·22 (0·91) −4·00 to −0·44 0·015
PANSS negative −1·02 (0·67) −2·35 to 0·30 0·13
PANSS general −3·63 (1·21) −5·99 to −1·27 0·003
Secondary outcomes
PSYRATS unusual beliefs cognitive −2·08 (0·82) −3·69 to −0·47 0·011
PSYRATS unusual beliefs emotion −0·70 (0·51) −1·71 to 0·30 0·17
PSYRATS voices cognitive −2·1 (0·95) −3·96 to −0·23 0·028
PSYRATS voices emotion −1·44 (1·06) −3·52 to 0·64 0·174
PSYRATS voices physical −1·76 (0·89) −3·51 to −0·02 0·048
QPR* 3·32 (1·9) −0·39 to 7·04 0·08
PSP* 5·47 (2·7) 0·18 to 10·77 0·043
BDI −0·73 (0·79) −2·29 to 0·83 0·357
SIAS −1·63 (3·17) −7·84 to 4·58 0·607
PANSS=positive and negative syndrome scale. PSYRATS=psychotic symptom rating scales. QPR=questionnaire on the 
process of recovery. PSP=personal and social performance. BDI=Beck depression inventory. SIAS=social interaction 
anxiety scale. *Negative estimates show that, on average, scores for the cognitive therapy group were lower than those 
for the treatment as usual group, except for QPR and PSP, for which a higher score is preferable.
Table 3: Estimates of treatment eff ect (common to all follow-up times)
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individual was also prescribed antidepressants, and of 
those in the treatment as usual group prescribed 
antipsychotics in the treatment phase, fi ve were also 
prescribed antidepressants. Additionally, nine partici-
pants in the cognitive therapy group were taking anti-
depressants in the treatment phase (with no new cases in 
follow-up), as were eight participants in the treatment as 
usual group (with 2 new cases in follow-up).
Discussion
To our knowledge, this study is the fi rst randomised trial 
of cognitive therapy for people with schizophrenia 
spectrum disorders not taking antipsychotic drugs. Our 
fi ndings show that cognitive therapy signifi cantly 
reduced the severity of psychiatric symptoms in this 
population. Additionally, cognitive therapy signifi cantly 
improved personal and social functioning and some 
dimensions of delusional beliefs (cognitive) and voice 
hearing (cognitive and physical). Therapy did not 
signifi cantly aff ect the amount of distress associated with 
delusional beliefs or voice hearing, or levels of depression, 
social anxiety, and self-rated recovery.
On average, neither group deteriorated over time, in a 
population that has been assumed to deteriorate without 
total adherence to drugs;34 in fact, some participants 
receiving treatment as usual  who were not taking drugs 
achieved good clinical outcomes, and more did with the 
addition of cognitive therapy. However, some individual 
patients not taking drugs did have deterioration and 
adverse events, and this fi nding was noted on both groups 
(additionally we might have missed some such events, in 
view of high rates of missing data and non-engagement 
with services). We also showed that cognitive therapy is 
an acceptable intervention for a population who are 
usually considered to  be very challenging to engage by 
mental health services, with low rates of drop out and 
withdrawal, and very few referrals refusing randomisation 
after assessment as eligible.
These results are consistent with fi ndings from 
clinical trials of cognitive therapy for psychosis to date. 
Most trials have shown that severity of psychiatric 
symptoms can be reduced over a moderate timeframe 
in people taking antipsychotic drugs, with an average 
eff ect size of 0·4.16 Our study found a similar eff ect size 
in people who had chosen not to take such drugs. 
Although this eff ect size is small to moderate,  the size 
on psychiatric symptoms in our study is similar to the 
median eff ect size reported for overall symptoms in a 
large meta-analysis of 15 antipsychotic drugs versus 
placebo (median 0·44).9 The baseline PANSS total 
scores for our trial are notably higher than for most 
trials of cognitive therapy for psychosis, suggesting that 
our results might be reasonably generalisable and are 
not attributable to participants being relatively well at 
study entry (our sample would correspond to a 
moderately ill population according to thresholds for 
the PANSS35). Indeed, many participants were regarded 
as challenging to engage by their clinical teams, with 
some being discharged as a result, and our therapists 
frequently had to work hard to engage them and identify 
a shared goal. Cognitive therapy seemed to be acceptable 
to this population. Because equal numbers of 
participants in each group started drugs, the eff ects 
noted are not likely to be due to drugs, especially 
because more participants in the treatment as usual 
group started antipsychotics during the initial treatment 
window. Examination of the improvement or 
deterioration in individuals who started drugs also 
suggests that the benefi ts are not likely to be attributable 
to antipsychotics.
Our trial shows methodological rigour in several ways. 
Importantly, we pre-specifi ed our primary and secondary 
outcomes, thus reducing the likelihood of type 1 errors. 
Furthermore, use of more than one site should increase 
generalisability to routine clinical service provision. 
However, our trial has some methodological diffi  culties. 
N Increase (deterioration) 0% change Reduction (improvement)
100% 75–100% 50–74% 25–49% 0–24% 0–24% 25–49% 50–74% 75–100%
CT (9 months) 22 1 (5%)* 0 0 1 (5%)* 3 (14%) 2 (9%)* 3 (14%)* 5 (23%)† 4 (18%) 3 (14%)†
TAU (9 months) 23 0 0 0 2 (9%) 2 (9%)* 2 (9%)* 9 (39%)‡ 5 (22%)† 2 (9%) 1 (4%)
CT (18 months) 17 0 0 1 (6%) 1 (6%) 0 0 4 (24%)† 4 (24%) 6 (35%)† 1 (6%)
TAU (18 months) 17 0 0 2 (12%) 2 (12%)† 3 (18%)* 1 (6%) 4 (24%)† 2 (12%) 2 (12%)* 1 (6%)
Data are n (%), unless otherwise indicated. CT=cognitive therapy. TAU=treatment as usual. *One participant commenced antipsychotic drugs, of the total number within each 
change category. †Two participants commenced antipsychotic drugs, of the total number within each change category. ‡Three participants commenced antipsychotic drugs, of 
the total number within each change category.
Table 4: Number of participants achieving improvement/deterioration on adjusted PANSS total scores at 9 and 18 months
CT plus TAU (n=37) TAU (n=37)
Participants 
admitted
Length of stay 
(days)
Participants 
admitted
Length of stay 
(days)
Voluntary 
admission
4 (11%) 12·25 (9·54) 1 (3%) 27·00 (0·00)
Compulsory 
admission
0 ·· 3 (8%) 42·00 (22·65)
Data are n (%) or mean (SD). CT=cognitive therapy. TAU=treatment as usual.
Table 5: Hospital admissions during the treatment phase
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We did not measure treatment exposure before study entry 
(except for recent antipsychotic drugs and cognitive 
therapy), so could not include this in our analyses. We did 
not correct for multiple comparisons (for example, using 
Bonferroni’s correction); however, we had only one primary 
outcome, and because this is a pilot study, application of a 
more stringent alpha level for secondary outcomes would 
have been overly conservative. The use of acceptance into 
an early intervention service as an alternative to diagnosis 
as inclusion criteria might limit the generalisability of our 
fi ndings to settings that do not have such specialist teams. 
Similarly, our exclusion of people who were in inpatient 
settings also limits generalisability to those with acute 
episodes needing hospital admission, and those who are 
referred to a clinical trial might not be representative of all 
participants who refuse drugs (although very few referred 
refused to participate). Our trial is also not likely to be 
generalisable to service users who are a great risk to 
themselves or the community, because they are likely to be 
managed with community treatment orders that require 
drug compliance. The absence of a control group that 
included non-specifi c factors such as contact time, warmth, 
and empathy, means that we cannot exclude the possibility 
that the recorded eff ects are due to such non-specifi c 
factors. Perhaps most importantly, our trial had low 
statistical power with a small sample size and a fairly high 
attrition rate. In view of the trend reported in trials of 
specifi c psychological therapies such as cognitive therapy 
for psychosis, which have shown that eff ect sizes are 
reduced when indices of study quality (such as adequate 
statistical power and active comparators) are controlled 
for,16 our eff ect sizes are probably infl ated. Therefore, an 
adequately powered defi nitive randomised controlled trial 
is needed. A larger defi nitive trial would allow for analysis 
of factors such as therapist eff ects and subgroups (eg, 
participants not taking any drugs).
Our study has several clinical implications, although 
they should be considered cautiously in view of the 
limitations of a pilot study. Because the largest factor in 
our participants’ choices not to take antipsychotics was 
side-eff ects,18 alternative, evidence-based treatments 
should be available to people who choose not to take 
antipsychotics (panel). The off er of informed choices to 
service users who retain decision-making capacity might 
be possible if there is no risk to self or others, as judged on 
the basis of a comprehensive risk assessment. Such 
informed choices would benefi t from a defi nitive trial that 
would increase confi dence in the validity of our fi ndings. 
We are not advocating that people who derive benefi t from 
antipsychotic drugs should consider discontinuation; 
rather, we are advocating for evidence-based alternatives 
for those who choose not to on the basis of reasons that 
might include side-eff ects or perceived ineffi  cacy (as many 
as half of all service users with schizophrenia spectrum 
disorders might choose not to take drugs5). A collaborative 
approach to decision making might  improve the response 
for patients who choose to take antipsychotics, because 
the quality of relationship with the prescribing clinician is 
associated with attitudes to and adherence with drugs.38 In 
this context, it is also worth noting that a fi fth of our 
participants started antipsychotic drugs some point after 
having originally chosen not to. Consistent with this 
approach, the recently published NICE guidelines for 
psychosis and schizophrenia in children and young 
people recommend that service users and carers should 
be entitled to choose psychosocial interventions, such as 
cognitive therapy, in the absence of antipsychotics.36
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Panel: Research in context
Systematic review
Although fi ndings from systematic reviews and 
meta-analyses1,16,36 show that robust evidence exists of the 
eff ectiveness of cognitive therapy for psychosis in addition to 
antipsychotics compared with treatment as usual, no 
randomised controlled trials have been done of cognitive 
therapy in people with psychotic disorders not taking 
antipsychotics. We searched the reference lists of the reviews 
mentioned above and a Cochrane review;37 furthermore, we 
searched CENTRAL, PubMed, and Current Controlled Trials. 
We limited the search to 2009–13, because the last search for 
the reviews was done in 2010. We searched titles and 
abstracts for “cognitive behavioural therapy”, “cognitive 
therapy”, “psychosis”, “schizophrenia” and “trial”, and limited 
our search to reports published in English.
Interpretation
Our fi ndings suggest that cognitive therapy is an acceptable, 
safe, and eff ective treatment alternative for people who choose 
not to take antipsychotics. Evidence-based treatments should 
be available to these people. A larger defi nitive trial is needed to 
confi rm the clinical implications of our pilot study.
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